for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Trillium Therapeutics Inc

TRIL.TO

Latest Trade

21.95CAD

Change

0.22(+1.01%)

Volume

9,989

Today's Range

21.72

 - 

21.95

52 Week Range

7.48

 - 

27.12

As of on the Toronto Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
21.73
Open
21.75
Volume
9,989
3M AVG Volume
3.96
Today's High
21.95
Today's Low
21.72
52 Week High
27.12
52 Week Low
7.48
Shares Out (MIL)
105.00
Market Cap (MIL)
2,281.54
Forward P/E
-20.60
Dividend (Yield %)
--

Next Event

Trillium Therapeutics Inc Extraordinary Shareholders Meeting

Latest Developments

More

Trillium Therapeutics Reports Second Quarter 2021 Operating And Financial Results

Trillium Therapeutics Reports First Quarter 2021 Operating And Financial Results

Trillium Therapeutics Files For Mixed Shelf Offering Size Not Disclosed

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Trillium Therapeutics Inc

Trillium Therapeutics Inc is a Canada-based clinical stage immuno-oncology company. The Company is engaged in developing therapies for the treatment of cancer. The Company is developing two clinical programs, TTI-621 and TTI-622, target CD47, a don’t eat me signal that blocks the ability of macrophages to phagocytose and destroy tumor cells. The TTI-621 is being evaluated in a multicenter, open-label phase I trial in patients with relapsed/refractory hematologic malignancies. The TTI-622 is Trillium’s second SIRPαFc fusion protein. TTI-622 consists of the same extracellular CD47-binding domain of human SIRPα as TTI-621 but has an immunoglobulin G4 (IgG4) Fc region instead of an IgG1 Fc. TTI-622 is being studied in a two-part, multicenter, open-label, phase Ia/Ib study in patients with advanced relapsed or refractory lymphoma or multiple myeloma (NCT03530683). It focuses on developing inhibitors of CD47, a checkpoint of the innate immune system.

Industry

Biotechnology & Drugs

Contact Info

2488 Dunwin Drive

MISSISSAUGA, ON

L5L 1J9

Canada

+1.416.5950627

http://www.trilliumtherapeutics.com/

Executive Leadership

Jan Skvarka

President, Chief Executive Officer, Director

James T. Parsons

Chief Financial Officer

Rosemary Harrison

Senior Vice President, Corporate Development and Strategy

Robert Uger

Chief Scientific Officer

Ingmar Bruns

Chief Medical Officer

Key Stats

2.50 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (USD)

2018

-2.244

2019

-1.650

2020

-0.700

2021(E)

-0.845
Price To Earnings (TTM)
--
Price To Sales (TTM)
42,879.56
Price To Book (MRQ)
7.54
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-25.83
Return on Equity (TTM)
-23.96

Latest News

Latest News

Pfizer to buy cancer drug developer Trillium in $2.3 billion deal

Pfizer Inc said on Monday it would buy Canadian drug developer Trillium Therapeutics Inc in a $2.26 billion deal to strengthen its arsenal of blood cancer therapies.

BRIEF-Trillium Therapeutics Provides Update On The Phase I Dose Escalation Study Of Its Cd47 Blocker Tti-622 At The Asco20 Virtual Scientific Program

* TRILLIUM THERAPEUTICS PROVIDES UPDATE ON THE PHASE I DOSE ESCALATION STUDY OF ITS CD47 BLOCKER TTI-622 AT THE ASCO20 VIRTUAL SCIENTIFIC PROGRAM

BRIEF-Trillium Therapeutics Posts Quarterly Loss Per Share $1.07

* TRILLIUM THERAPEUTICS REPORTS FIRST QUARTER 2020 FINANCIAL AND OPERATING RESULTS

BRIEF-Trillium Therapeutics To Present Data On Lymphoma Treatment

* TRILLIUM THERAPEUTICS TO PRESENT DATA ON CD47 BLOCKER TTI-622 IN ADVANCED RELAPSED OR REFRACTORY LYMPHOMA AT THE ASCO20 VIRTUAL SCIENTIFIC PROGRAM Source text for Eikon: Further company coverage:

BRIEF-Trillium Therapeutics Says May Sell, Through Agent, Shares Of Up To $50 Mln

* TRILLIUM THERAPEUTICS ANNOUNCES “AT-THE-MARKET” EQUITY PROGRAM

BRIEF-Trillium Therapeutics Entered Sales Agreement Relating To Sale Of Common Shares

* TRILLIUM THERAPEUTICS INC - ENTERED SALES AGREEMENT RELATING TO SALE OF COMMON SHARES

BRIEF-Trillium Therapeutics Inc Files For Mixed Shelf Of Up To $250 Million

* TRILLIUM THERAPEUTICS INC FILES FOR MIXED SHELF OF UP TO $250 MILLION – SEC FILING Source text: [https://bit.ly/2XZsHTt] Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Trillium Expects A Slowdown In New Patient Enrolment In Its Tti-621 And Tti-622 Dose Escalation Studies

* TRILLIUM THERAPEUTICS PROVIDES BUSINESS UPDATE IN RESPONSE TO THE COVID-19 PANDEMIC

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up